Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galactosidase A

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	2

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-000667-24-IT (EUCTR)	28/03/2022	23/09/2021	A Phase I/II Study to Assess theSafety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosida ...	A Phase I/II, Multicenter, Open-Label, SingleDose, Dose-Ranging Study to Assess theSafety and Tolera ...	Fabry Disease (X-linked lysosomal storage disease) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galact ...	Sangamo Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 1;Phase 2	United States;Taiwan;Canada;Australia;Germany;United Kingdom;Italy
2	EUCTR2019-000667-24-GB (EUCTR)	12/11/2019	19/03/2019	A Phase I/II Study to Assess theSafety and Tolerability of ST-920, arAAV2/6 Human Alpha Galactosidas ...	A Phase I/II, Multicenter, Open-Label, SingleDose, Dose-Ranging Study to Assess theSafety and Tolera ...	Fabry Disease (X-linked lysosomal storage disease) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galact ...	Sangamo Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	30	Phase 1;Phase 2	United States;United Kingdom

First Previous1Next Last